Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. [electronic resource]
Producer: 20150219Description: 27-34 p. digitalISSN:- 1468-2060
- Adult
- Aged
- Antirheumatic Agents -- therapeutic use
- Arthritis, Rheumatoid -- diagnosis
- Drug Therapy, Combination -- methods
- Early Medical Intervention
- Female
- Glucocorticoids -- therapeutic use
- Humans
- Induction Chemotherapy -- methods
- Isoxazoles -- therapeutic use
- Leflunomide
- Male
- Methotrexate -- therapeutic use
- Middle Aged
- Prednisone -- therapeutic use
- Risk Assessment
- Severity of Illness Index
- Sulfasalazine -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.